

Halozyme – HyQvia Approval in EU and Upcoming milestones = Upside

<https://marketpublishers.com/r/HA85A0458DAEN.html>

Date: May 2013

Pages: 4

Price: US\$ 140.00 (Single User License)

ID: HA85A0458DAEN

Abstracts

Approval of HyQvia (L, 10% Gammagard liquid + rHuPH20, partnered with Baxter for primary immunodeficiencies, PI) in Europe increases the probability of approval of Herceptin SC and MabThera SC in 2Q13 and YE13 respectively. Clarity on the timelines of approval of HyQvia SC in US is expected this quarter. HYLENEX (L, rHuPH20, adjuvant to increase the absorption and dispersion of other injected drugs) has gained 50% of market share in 16 months of launch showing acceptability of Halozyme's (HALO) ENHANZE platform (recombinant human hyaluronidase, rHuPH20 use in the delivery of biologics- switching from IV injections to SC). Data from PEGPH20 in pancreatic cancer (ASCO 2013) boosted the stock and we expect further upside from... For more detail, please read our report released on May 24, 2013, titled, "HyQvia Approval in EU and Upcoming milestones = Upside".

I would like to order

Product name: Halozyme – HyQvia Approval in EU and Upcoming milestones = Upside

Product link: <https://marketpublishers.com/r/HA85A0458DAEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HA85A0458DAEN.html>